FDA Accepts Supplement Application for REZZAYO (Rezafungin Acetate)
The FDA has accepted a supplemental application for REZZAYO, an antifungal agent containing Rezafungin Acetate.
Asset / Drug
Drug and asset intelligence for Mundipharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.